Tromexan, which is administered orally, appears to have the advantages of more rapid utilization and more rapid cessation of action than dicumarol, although the mode of action is similar in that it produces a hypoprothrombinemia. It does require accurate prothrombin tests for …

Tromexan is a safer drug than Dicumarol; its shorter action and larger daily dose allow more ready regulation of the anticoagulant therapy. The risks of prolonged overdosage with the associated hemorrhagic tendencies are correspondingly reduced.

The purposes of this paper are to discuss the principles underlying the administration of tromexan, which differ from those of dicoumarol in important respects; to present a scheme of dosage that has proved effective in lowering the blood-prothrombin and keeping it at a safe level; to describe the difficulties commonly met, such as increasing re...

An evaluation of the comparative actions of Tromexan and dicumarol is herein reported. Five hundred fourteen patients were studied; a total experience of 6,642 days of Tromexan therapy and 5,006 days of dicumarol therapy were reviewed and analyzed.

The use of heparin and dicumarol has provided important information regarding the effectiveness and the difficulties of anticoagulant therapy. Neither, however, is an ideal anticoagulant; therefore a search for new substances with advantages over them must be continued. Tromexan, which is administered orally, appears to have the advantages of …

If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password

A new coumarin drug, Tromexan, was evaluated clinically in 116 patients on therapeutic and prophylactic regimens. 2. Control prothrombin times were taken on all patients.

Tromexan is a safer drug than Dicumarol; its shorter action and larger daily dose allow more ready regulation of the anticoagulant therapy. The risks of prolonged overdosage with the associated hemorrhagic tendencies are correspondingly reduced.

The claims for tromexan are based on its quicker action and more rapid destruction and excretion. If Reinis and Kubik (1948) are right in their evaluation of its potency, its more rapid action cannot be due to increased dosage but may be associated with its lesser stability.

Tromexan in the treatment of coronary thrombosis. Tromexan in the treatment of coronary thrombosis. Tromexan in the treatment of coronary thrombosis Am Heart J. 1951 Dec;42(6):864-75. doi: 10.1016/0002-8703(51)90058-0. Authors J A TULLOCH, A R GILCHRIST. PMID: ...